Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2024 and highlighted recent business progress.
Cambridge: Harbour BioMed, a global biopharmaceutical company has announced a global strategic collaboration with AstraZeneca ...
Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...
Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...
Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.
Harbour BioMed inks collaboration with AstraZeneca to discover and develop next-generation therapeutic antibodies: Shanghai & Rotterdam, The Netherlands Tuesday, March 25, 2025, 1 ...
Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences, said, "Toripalimab's approval in Singapore represents our ...
An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha-gal syndrome, ...
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients ...
News Medical on MSN3d
Antibody-Based Therapy Shows Promise Against Lethal Fungal InfectionEarly tests suggest that an antibody-based therapy is safe, with no harmful effects on healthy cells, suggesting that it ...
The damage to blood vessels is concerning because it's how antifungal drug therapy is delivered to the infection site. "Our humanized monoclonal antibody allows antifungal drug therapy to reach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback